Magnetic resonance spectroscopy assessment of brain injury after moderate hypothermia in neonatal encephalopathy: a prospective multicentre cohort study.


Journal

The Lancet. Neurology
ISSN: 1474-4465
Titre abrégé: Lancet Neurol
Pays: England
ID NLM: 101139309

Informations de publication

Date de publication:
01 2019
Historique:
received: 16 06 2018
revised: 21 08 2018
accepted: 26 08 2018
pubmed: 19 11 2018
medline: 6 5 2020
entrez: 19 11 2018
Statut: ppublish

Résumé

In neonatal encephalopathy, the clinical manifestations of injury can only be reliably assessed several years after an intervention, complicating early prognostication and rendering trials of promising neuroprotectants slow and expensive. We aimed to determine the accuracy of thalamic proton magnetic resonance (MR) spectroscopy (MRS) biomarkers as early predictors of the neurodevelopmental abnormalities observed years after neonatal encephalopathy. We did a prospective multicentre cohort study across eight neonatal intensive care units in the UK and USA, recruiting term and near-term neonates who received therapeutic hypothermia for neonatal encephalopathy. We excluded infants with life-threatening congenital malformations, syndromic disorders, neurometabolic diseases, or any alternative diagnoses for encephalopathy that were apparent within 6 h of birth. We obtained T Between Jan 29, 2013, and June 25, 2016, we recruited 223 infants who all underwent MRI and MRS at a median age of 7 days (IQR 5-10), with 190 (85%) followed up for neurological examination at a median age of 23 months (20-25). Of those followed up, 31 (16%) had moderate or severe disability, including one death. Multiple logistic regression analysis could not be done because thalamic N-acetylaspartate (NAA) concentration alone accurately predicted an adverse neurodevelopmental outcome (area under the curve [AUC] of 0·99 [95% CI 0·94-1·00]; sensitivity 100% [74-100]; specificity 97% [90-100]; n=82); the models would not converge when any additional variable was examined. The AUC (95% CI) of clinical examination at 6 h (n=190) and at discharge (n=167) were 0·72 (0·65-0·78) and 0·60 (0·53-0·68), respectively, and the AUC of abnormal amplitude integrated EEG at 6 h (n=169) was 0·73 (0·65-0·79). On conventional MRI (n=190), cortical injury had an AUC of 0·67 (0·60-0·73), basal ganglia or thalamic injury had an AUC of 0·81 (0·75-0·87), and abnormal signal in the posterior limb of internal capsule (PLIC) had an AUC of 0·82 (0·76-0·87). Fractional anisotropy of PLIC (n=65) had an AUC of 0·82 (0·76-0·87). MRS metabolite peak-area ratios (n=160) of NAA-creatine (<1·29) had an AUC of 0·79 (0·72-0·85), of NAA-choline had an AUC of 0·74 (0·66-0·80), and of lactate-NAA (>0·22) had an AUC of 0·94 (0·89-0·97). Thalamic proton MRS measures acquired soon after birth in neonatal encephalopathy had the highest accuracy to predict neurdevelopment 2 years later. These methods could be applied to increase the power of neuroprotection trials while reducing their duration. National Institute for Health Research UK.

Sections du résumé

BACKGROUND
In neonatal encephalopathy, the clinical manifestations of injury can only be reliably assessed several years after an intervention, complicating early prognostication and rendering trials of promising neuroprotectants slow and expensive. We aimed to determine the accuracy of thalamic proton magnetic resonance (MR) spectroscopy (MRS) biomarkers as early predictors of the neurodevelopmental abnormalities observed years after neonatal encephalopathy.
METHODS
We did a prospective multicentre cohort study across eight neonatal intensive care units in the UK and USA, recruiting term and near-term neonates who received therapeutic hypothermia for neonatal encephalopathy. We excluded infants with life-threatening congenital malformations, syndromic disorders, neurometabolic diseases, or any alternative diagnoses for encephalopathy that were apparent within 6 h of birth. We obtained T
FINDINGS
Between Jan 29, 2013, and June 25, 2016, we recruited 223 infants who all underwent MRI and MRS at a median age of 7 days (IQR 5-10), with 190 (85%) followed up for neurological examination at a median age of 23 months (20-25). Of those followed up, 31 (16%) had moderate or severe disability, including one death. Multiple logistic regression analysis could not be done because thalamic N-acetylaspartate (NAA) concentration alone accurately predicted an adverse neurodevelopmental outcome (area under the curve [AUC] of 0·99 [95% CI 0·94-1·00]; sensitivity 100% [74-100]; specificity 97% [90-100]; n=82); the models would not converge when any additional variable was examined. The AUC (95% CI) of clinical examination at 6 h (n=190) and at discharge (n=167) were 0·72 (0·65-0·78) and 0·60 (0·53-0·68), respectively, and the AUC of abnormal amplitude integrated EEG at 6 h (n=169) was 0·73 (0·65-0·79). On conventional MRI (n=190), cortical injury had an AUC of 0·67 (0·60-0·73), basal ganglia or thalamic injury had an AUC of 0·81 (0·75-0·87), and abnormal signal in the posterior limb of internal capsule (PLIC) had an AUC of 0·82 (0·76-0·87). Fractional anisotropy of PLIC (n=65) had an AUC of 0·82 (0·76-0·87). MRS metabolite peak-area ratios (n=160) of NAA-creatine (<1·29) had an AUC of 0·79 (0·72-0·85), of NAA-choline had an AUC of 0·74 (0·66-0·80), and of lactate-NAA (>0·22) had an AUC of 0·94 (0·89-0·97).
INTERPRETATION
Thalamic proton MRS measures acquired soon after birth in neonatal encephalopathy had the highest accuracy to predict neurdevelopment 2 years later. These methods could be applied to increase the power of neuroprotection trials while reducing their duration.
FUNDING
National Institute for Health Research UK.

Identifiants

pubmed: 30447969
pii: S1474-4422(18)30325-9
doi: 10.1016/S1474-4422(18)30325-9
pmc: PMC6291458
pii:
doi:

Substances chimiques

Aspartic Acid 30KYC7MIAI
N-acetylaspartate 997-55-7

Banques de données

ClinicalTrials.gov
['NCT01309711']

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

35-45

Subventions

Organisme : Department of Health
ID : HCS DRF-2014-05-013
Pays : United Kingdom
Organisme : Department of Health
ID : ICA-CDRF-2016-02-071
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR/CS/010/022
Pays : United Kingdom
Organisme : Department of Health
ID : NIHR300118
Pays : United Kingdom

Investigateurs

Peter J Lally (PJ)
Paolo Montaldo (P)
Vânia Oliveira (V)
Aung Soe (A)
Ravi Swamy (R)
Paul Bassett (P)
Josephine Mendoza (J)
Gaurav Atreja (G)
Ujwal Kariholu (U)
Santosh Pattnayak (S)
Palaniappan Sashikumar (P)
Helen Harizaj (H)
Martin Mitchell (M)
Vijayakumar Ganesh (V)
Sundeeep Harigopal (S)
Jennifer Dixon (J)
Philip English (P)
Paul Clarke (P)
Priya Muthukumar (P)
Prakash Satodia (P)
Sarah Wayte (S)
Laurence J Abernethy (LJ)
Kiran Yajamanyam (K)
Alan Bainbridge (A)
David Price (D)
Angela Huertas (A)
David J Sharp (DJ)
Vaneet Kalra (V)
Sanjay Chawla (S)
Seetha Shankaran (S)
Sudhin Thayyil (S)

Commentaires et corrections

Type : CommentIn
Type : CommentIn
Type : CommentIn

Informations de copyright

Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY 4.0 license. Published by Elsevier Ltd.. All rights reserved.

Références

Pediatrics. 1999 Jun;103(6 Pt 1):1263-71
pubmed: 10353940
Ann Neurol. 1992 Jan;31(1):14-21
pubmed: 1543346
Lancet. 2005 Mar 5-11;365(9462):891-900
pubmed: 15752534
Neurology. 2007 Nov 13;69(20):1942-52
pubmed: 17998486
Lancet Neurol. 2010 Jan;9(1):39-45
pubmed: 19896902
Pediatrics. 2010 Feb;125(2):e382-95
pubmed: 20083516
Arch Pediatr Adolesc Med. 2012 Jul 1;166(7):634-40
pubmed: 22751877
Arch Dis Child Fetal Neonatal Ed. 2012 Nov;97(6):F398-404
pubmed: 23080477
Pediatrics. 2013 Jan;131(1):88-98
pubmed: 23248219
Cochrane Database Syst Rev. 2013 Jan 31;(1):CD003311
pubmed: 23440789
Neuroradiology. 2013 Aug;55(8):1017-1025
pubmed: 23703033
Radiology. 2014 Mar;270(3):658-79
pubmed: 24568703
Curr Pediatr Rev. 2014;10(1):28-36
pubmed: 25055861
Curr Pediatr Rev. 2014;10(1):37-47
pubmed: 25055862
JAMA. 2014 Dec 24-31;312(24):2629-39
pubmed: 25536254
BMJ Open. 2015 Sep 30;5(9):e008912
pubmed: 26423856
Lancet Neurol. 2016 Feb;15(2):145-153
pubmed: 26708675
Arch Dis Child Fetal Neonatal Ed. 2017 Mar;102(2):F147-F152
pubmed: 27553589
J Perinatol. 2017 Jun;37(6):684-689
pubmed: 28252661
Dev Neurosci. 2017;39(1-4):36-48
pubmed: 28448965
Magn Reson Imaging. 2017 Oct;42:82-87
pubmed: 28619605
JAMA. 2017 Jul 4;318(1):57-67
pubmed: 28672318
Neuroimage. 2017 Nov 1;161:149-170
pubmed: 28826946
Trials. 2017 Sep 18;18(1):432
pubmed: 28923118
Arch Dis Child Fetal Neonatal Ed. 2018 Jul;103(4):F388-F390
pubmed: 28942433
J Pediatr. 2018 Jan;192:22-32
pubmed: 29031859
JAMA. 2017 Oct 24;318(16):1550-1560
pubmed: 29067428
Neonatology. 2018;113(4):331-338
pubmed: 29514165
Clin Perinatol. 2018 Jun;45(2):241-255
pubmed: 29747886
Radiology. 2018 Sep;288(3):840-848
pubmed: 29893645

Auteurs

Peter J Lally (PJ)

Centre for Perinatal Neuroscience, Imperial College London, London, UK.

Paolo Montaldo (P)

Centre for Perinatal Neuroscience, Imperial College London, London, UK.

Vânia Oliveira (V)

Centre for Perinatal Neuroscience, Imperial College London, London, UK.

Aung Soe (A)

Oliver Fisher Neonatal Unit, Medway NHS Foundation Trust, Kent, UK.

Ravi Swamy (R)

Centre for Perinatal Neuroscience, Imperial College London, London, UK.

Paul Bassett (P)

Statsconsultancy, Amersham, UK.

Josephine Mendoza (J)

Centre for Perinatal Neuroscience, Imperial College London, London, UK.

Gaurav Atreja (G)

Neonatal Unit, Imperial College Healthcare NHS Trust, London, UK.

Ujwal Kariholu (U)

Neonatal Unit, Imperial College Healthcare NHS Trust, London, UK.

Santosh Pattnayak (S)

Oliver Fisher Neonatal Unit, Medway NHS Foundation Trust, Kent, UK.

Palaniappan Sashikumar (P)

Oliver Fisher Neonatal Unit, Medway NHS Foundation Trust, Kent, UK.

Helen Harizaj (H)

Oliver Fisher Neonatal Unit, Medway NHS Foundation Trust, Kent, UK.

Martin Mitchell (M)

Oliver Fisher Neonatal Unit, Medway NHS Foundation Trust, Kent, UK.

Vijayakumar Ganesh (V)

Oliver Fisher Neonatal Unit, Medway NHS Foundation Trust, Kent, UK.

Sundeep Harigopal (S)

Neonatal Unit, Royal Victoria Infirmary, Newcastle, UK.

Jennifer Dixon (J)

Neonatal Unit, Royal Victoria Infirmary, Newcastle, UK.

Philip English (P)

Neonatal Unit, Royal Victoria Infirmary, Newcastle, UK.

Paul Clarke (P)

Neonatal Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.

Priya Muthukumar (P)

Neonatal Unit, Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich, UK.

Prakash Satodia (P)

Neonatal Unit, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.

Sarah Wayte (S)

Neonatal Unit, University Hospitals Coventry and Warwickshire NHS Trust, Coventry, UK.

Laurence J Abernethy (LJ)

Neonatal Unit, Liverpool Women's NHS Foundation Trust, Liverpool, UK.

Kiran Yajamanyam (K)

Neonatal Unit, Liverpool Women's NHS Foundation Trust, Liverpool, UK.

Alan Bainbridge (A)

Neonatal Unit, University College London Hospitals NHS Foundation Trust, London, UK.

David Price (D)

Neonatal Unit, University College London Hospitals NHS Foundation Trust, London, UK.

Angela Huertas (A)

Neonatal Unit, University College London Hospitals NHS Foundation Trust, London, UK.

David J Sharp (DJ)

Computational, Cognitive and Clinical Neuroimaging Laboratory, Imperial College London, London, UK.

Vaneet Kalra (V)

Neonatal-Perinatal Medicine, Wayne State University, Detroit, MI, USA.

Sanjay Chawla (S)

Neonatal-Perinatal Medicine, Wayne State University, Detroit, MI, USA.

Seetha Shankaran (S)

Neonatal-Perinatal Medicine, Wayne State University, Detroit, MI, USA.

Sudhin Thayyil (S)

Centre for Perinatal Neuroscience, Imperial College London, London, UK. Electronic address: s.thayyil@imperial.ac.uk.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH